Is lipoxins A₄ a better alternative to anti-VEGF and anti-TNF-α antibody to prevent and treat age-related macular degeneration, diabetic macular edema and retinopathy?
Undurti N
UN
Das
D000906:Antibodies / Q000627:therapeutic use*; D003930:Diabetic Retinopathy / Q000188:drug therapy* / Q000517:prevention & control; D006801:Humans; D044045:Lipoxins / Q000627:therapeutic use*; D008268:Macular Degeneration / Q000188:drug therapy* / Q000517:prevention & control; D008269:Macular Edema / Q000188:drug therapy* / Q000517:prevention & control
D000906:Antibodies; D044045:Lipoxins; C040527:lipoxin A4